Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GTXi (GTXI) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (46)	3/3/2008 7:40:49 AM
From: kenhott	Read Replies (1) \| Respond to of 85

Toremifene works by inhibiting bone resorption. The same as the bisphosphonates. Studies with clodronate(?sp?), a bisphosphonate, have shown positive effects in at least a couple of good trials on bone mets in breast cancer patients. But I know of one study in non-met prostate with clodronate that showed a non-stat signal in greater bone mets and I believe also death. That study had n~500 and a follow up time of like 10 years. What does a non-stat trend mean in the current FDA given the action of toremifene with a SPA?? Unfortunately the prostate data came after the SPA. Bone mets are a big problem in breast and prostate. I was just wondering with the SPA (2003??) maybe the company has attempted to address this issue in a conference call. I don't have answers, just questions.